Loading page content…
Loading page content…
| Source: | Find a Tender Service (FTS) |
| Buyer: | CARDIFF UNIVERSITY |
| Main Category: | Goods |
| Procurement Method: | Direct award |
| Tender Status: | Complete |
| Estimated Value (ex. VAT): | Not specified |
| Release Date: | 24 October 2025 |
| Application Deadline: | — |
| Procurement ID (OCID): | ocds-h6vhtk-05d2df |
| Notice Reference: | 068032-2025 |
View Original Notice
Access the full notice on the official portal
Cardiff University's School of Medicine is procuring the manufacture of a novel investigational medicinal product (IMP), Triiodothyronine sulphate (T3S), for use in a Phase 2b clinical trial. The service includes the production of the active pharmaceutical ingredient (API), the IMP, and the finished drug formulation (FDF) in blister packs. This bespoke drug is intended for hypothyroid patients with a specific genetic variation affecting thyroid hormone metabolism. The supplier will manufacture the product to GMP standards, using a validated Route of Synthesis supported by existing preclinical and toxicology data.
Published contracts in the last 12 months
36
total contracts
£19.8m
total value
£2,824,370
average contract size
Typical categories
Pipeline status
Not addedContract imported automatically · AI writes the response
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →